EICOSIS LLC

Davis, CA · Biotech · Private

Small-molecule soluble epoxide hydrolase (sEH) inhibitor for treating chemotherapy-induced peripheral neuropathy pain

Grants
$2.3M
7 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
15
2 granted · 13 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · sEH Inhibitors to Treat Neuropathic Pain$731,876
Federal grantDepartment of Health and Human Services · Phase II · sEH Inhibitors to Treat Neuropathic Pain$76,094
Federal grantDepartment of Health and Human Services · Phase II · sEH Inhibitors to Treat Neuropathic Pain$705,128
Federal grantDepartment of Health and Human Services · Phase II · sEH Inhibitors to Treat Neuropathic Pain$1,382
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain$268,196
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain$268,196
Federal grantDepartment of Health and Human Services · Phase I · Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling$279,136
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2916VACCINEX, INC.—$44M
2917STELLATE DNA LLC——
2918Propeller Bio——
2919EICOSIS LLC——
2920PARION SCIENCES, INC.——
2921VINCERE BIOSCIENCES INC——
2922AADI, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 15
  • Polymorphic Forms Of A Soluble Epoxide Hydrolase Inhibitor And Formulations Thereofapplication
  • Co-crystal Of Sorafenib Derivatives And Process For Preparation Thereofgranted
  • Potent Soluble Epoxide Hydrolase Inhibitorsgranted
  • Soluble Epoxide Hydrolase Inhibitors And Methods Of Use Thereofapplication
  • Polymorphic Forms Of A Soluble Epoxide Hydrolase Inhibitor And Formulations Thereofapplication
  • Polymorphic Forms Of A Soluble Epoxide Hydrolase Inhibitor And Formulations Thereofapplication
  • Polymorphic Forms Of A Soluble Epoxide Hydrolase Inhibitor And Formulations Thereofapplication
  • Methods Of Treating Alzheimer's Disease Using Slow Tight Binding Soluble Epoxide Hydrolase Inhibitorsapplication
  • Methods For Detecting And Treating Infectionapplication
  • Methods Of Treating Alzheimer's Disease Using Slow Tight Binding Soluble Epoxide Hydrolase Inhibitorsapplication
  • Co-crystal Of Sorafenib Derivatives And Process For Preparation Thereofapplication
  • Methods For Treating Or Preventing Occular Diseasesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.